Most published systematic reviews of remdesivir for COVID-19 were redundant and lacked currency.

ABSTRACT:

Objective

To investigate the completeness and currency of published systematic reviews of remdesivir for COVID-19 and to compare this with a living guidelines approach.

Study design and setting

In this cross-sectional study, we searched Europe PMC on May 20, 2021 for systematic reviews of remdesivir (including preprints, living review updates). Completeness and currency were based on the inclusion of four major randomized trials of remdesivir available at the time of publication of the review (including as preliminary results and preprints).

Results

We included 38 reviews (45 reports), equivalent to a new publication every 9 days. 23 (51%) reports were out of date at the time of publication. Eleven reviews that were current on publication had a median survival time of

SUBMITTER: McDonald S 

PROVIDER: S-EPMC8858007 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature